The role of immunophilin ligands in nerve regeneration

Edward C. Toll, Alexander M. Seifalian, Martin A. Birchall

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Tacrolimus (FK506) is a widely used immunosuppressant in organ transplantation. However, it also has neurotrophic activity that occurs independently of its immunosuppressive effects. Other neurotrophic immunophilin ligands that do not exhibit immunosuppression have subsequently been developed and studied in various models of nerve injury. This article reviews the literature on the use of tacrolimus and other immunophilin ligands in peripheral nerve, cranial nerve and spinal cord injuries. The most convincing evidence of enhanced nerve regeneration is seen with systemic administration of tacrolimus in peripheral nerve injury, although clinical use is limited due to its immunosuppressive side effects. Local tacrolimus delivery to the site of nerve repair in peripheral and cranial nerve injury is less effective but requires further investigation. Tacrolimus can enhance outcomes in nerve allograft reconstruction and accelerates reinnervation of complex functional allograft transplants. Other non-immunosuppressive immunophilins ligands such as V-10367 and FK1706 demonstrate enhanced neuroregeneration in the peripheral nervous system and CNS. Mixed results are found in the application of immunophilin ligands to treat spinal cord injury. Immunophilin ligands have great potential in the treatment of nerve injury, but further preclinical studies are necessary to permit translation into clinical trials.

Original languageEnglish (US)
Pages (from-to)635-652
Number of pages18
JournalRegenerative Medicine
Volume6
Issue number5
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Immunophilins
Nerve Regeneration
Tacrolimus
Ligands
Immunosuppressive Agents
Peripheral Nerve Injuries
Spinal Cord Injuries
Allografts
Transplantation (surgical)
Cranial Nerve Injuries
Transplants
Neurology
Cranial Nerves
Peripheral Nervous System
Wounds and Injuries
Organ Transplantation
Peripheral Nerves
Repair
Immunosuppression
Clinical Trials

Keywords

  • immunophilin ligand
  • nerve regeneration
  • peripheral nerves
  • tacrolimus

ASJC Scopus subject areas

  • Biomedical Engineering
  • Embryology

Cite this

Toll, E. C., Seifalian, A. M., & Birchall, M. A. (2011). The role of immunophilin ligands in nerve regeneration. Regenerative Medicine, 6(5), 635-652. https://doi.org/10.2217/rme.11.43

The role of immunophilin ligands in nerve regeneration. / Toll, Edward C.; Seifalian, Alexander M.; Birchall, Martin A.

In: Regenerative Medicine, Vol. 6, No. 5, 09.2011, p. 635-652.

Research output: Contribution to journalArticle

Toll, EC, Seifalian, AM & Birchall, MA 2011, 'The role of immunophilin ligands in nerve regeneration', Regenerative Medicine, vol. 6, no. 5, pp. 635-652. https://doi.org/10.2217/rme.11.43
Toll, Edward C. ; Seifalian, Alexander M. ; Birchall, Martin A. / The role of immunophilin ligands in nerve regeneration. In: Regenerative Medicine. 2011 ; Vol. 6, No. 5. pp. 635-652.
@article{e04b3dd68ee143f5b52c80fb89731799,
title = "The role of immunophilin ligands in nerve regeneration",
abstract = "Tacrolimus (FK506) is a widely used immunosuppressant in organ transplantation. However, it also has neurotrophic activity that occurs independently of its immunosuppressive effects. Other neurotrophic immunophilin ligands that do not exhibit immunosuppression have subsequently been developed and studied in various models of nerve injury. This article reviews the literature on the use of tacrolimus and other immunophilin ligands in peripheral nerve, cranial nerve and spinal cord injuries. The most convincing evidence of enhanced nerve regeneration is seen with systemic administration of tacrolimus in peripheral nerve injury, although clinical use is limited due to its immunosuppressive side effects. Local tacrolimus delivery to the site of nerve repair in peripheral and cranial nerve injury is less effective but requires further investigation. Tacrolimus can enhance outcomes in nerve allograft reconstruction and accelerates reinnervation of complex functional allograft transplants. Other non-immunosuppressive immunophilins ligands such as V-10367 and FK1706 demonstrate enhanced neuroregeneration in the peripheral nervous system and CNS. Mixed results are found in the application of immunophilin ligands to treat spinal cord injury. Immunophilin ligands have great potential in the treatment of nerve injury, but further preclinical studies are necessary to permit translation into clinical trials.",
keywords = "immunophilin ligand, nerve regeneration, peripheral nerves, tacrolimus",
author = "Toll, {Edward C.} and Seifalian, {Alexander M.} and Birchall, {Martin A.}",
year = "2011",
month = "9",
doi = "10.2217/rme.11.43",
language = "English (US)",
volume = "6",
pages = "635--652",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - The role of immunophilin ligands in nerve regeneration

AU - Toll, Edward C.

AU - Seifalian, Alexander M.

AU - Birchall, Martin A.

PY - 2011/9

Y1 - 2011/9

N2 - Tacrolimus (FK506) is a widely used immunosuppressant in organ transplantation. However, it also has neurotrophic activity that occurs independently of its immunosuppressive effects. Other neurotrophic immunophilin ligands that do not exhibit immunosuppression have subsequently been developed and studied in various models of nerve injury. This article reviews the literature on the use of tacrolimus and other immunophilin ligands in peripheral nerve, cranial nerve and spinal cord injuries. The most convincing evidence of enhanced nerve regeneration is seen with systemic administration of tacrolimus in peripheral nerve injury, although clinical use is limited due to its immunosuppressive side effects. Local tacrolimus delivery to the site of nerve repair in peripheral and cranial nerve injury is less effective but requires further investigation. Tacrolimus can enhance outcomes in nerve allograft reconstruction and accelerates reinnervation of complex functional allograft transplants. Other non-immunosuppressive immunophilins ligands such as V-10367 and FK1706 demonstrate enhanced neuroregeneration in the peripheral nervous system and CNS. Mixed results are found in the application of immunophilin ligands to treat spinal cord injury. Immunophilin ligands have great potential in the treatment of nerve injury, but further preclinical studies are necessary to permit translation into clinical trials.

AB - Tacrolimus (FK506) is a widely used immunosuppressant in organ transplantation. However, it also has neurotrophic activity that occurs independently of its immunosuppressive effects. Other neurotrophic immunophilin ligands that do not exhibit immunosuppression have subsequently been developed and studied in various models of nerve injury. This article reviews the literature on the use of tacrolimus and other immunophilin ligands in peripheral nerve, cranial nerve and spinal cord injuries. The most convincing evidence of enhanced nerve regeneration is seen with systemic administration of tacrolimus in peripheral nerve injury, although clinical use is limited due to its immunosuppressive side effects. Local tacrolimus delivery to the site of nerve repair in peripheral and cranial nerve injury is less effective but requires further investigation. Tacrolimus can enhance outcomes in nerve allograft reconstruction and accelerates reinnervation of complex functional allograft transplants. Other non-immunosuppressive immunophilins ligands such as V-10367 and FK1706 demonstrate enhanced neuroregeneration in the peripheral nervous system and CNS. Mixed results are found in the application of immunophilin ligands to treat spinal cord injury. Immunophilin ligands have great potential in the treatment of nerve injury, but further preclinical studies are necessary to permit translation into clinical trials.

KW - immunophilin ligand

KW - nerve regeneration

KW - peripheral nerves

KW - tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=80052911048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052911048&partnerID=8YFLogxK

U2 - 10.2217/rme.11.43

DO - 10.2217/rme.11.43

M3 - Article

VL - 6

SP - 635

EP - 652

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

IS - 5

ER -